Bicycle Therapeutics (NASDAQ:BCYC) Price Target Lowered to $8.00 at Citizens Jmp

Bicycle Therapeutics (NASDAQ:BCYC) had its price objective decreased by Citizens Jmp from $12.00 to $8.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

Several other brokerages also recently weighed in on BCYC. Jefferies Financial Group upgraded Bicycle Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 17th. Truist Financial set a $8.00 price target on shares of Bicycle Therapeutics in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Needham & Company LLC cut their target price on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Morgan Stanley restated a “sell” rating and issued a $13.00 price target on shares of Bicycle Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $14.50.

Bicycle Therapeutics Trading Down 7.3%

NASDAQ BCYC opened at $4.70 on Wednesday. The stock has a market cap of $326.04 million, a PE ratio of -1.49 and a beta of 1.65. The stock has a fifty day simple moving average of $5.87 and a 200-day simple moving average of $6.79. Bicycle Therapeutics has a twelve month low of $4.59 and a twelve month high of $9.94.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.71. Bicycle Therapeutics had a negative net margin of 301.66% and a negative return on equity of 32.40%. The firm had revenue of $47.96 million during the quarter, compared to analysts’ expectations of $7.08 million. Research analysts predict that Bicycle Therapeutics will post -3.06 EPS for the current year.

Insider Activity

In related news, CFO Alethia Young sold 4,334 shares of Bicycle Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total transaction of $28,127.66. Following the sale, the chief financial officer owned 87,081 shares of the company’s stock, valued at $565,155.69. The trade was a 4.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin Lee sold 10,989 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the completion of the transaction, the chief executive officer owned 618,996 shares in the company, valued at $3,998,714.16. This represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 38,029 shares of company stock worth $251,966 over the last ninety days. Corporate insiders own 22.90% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Assetmark Inc. lifted its position in Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after purchasing an additional 1,552 shares during the last quarter. Clearstead Advisors LLC boosted its position in shares of Bicycle Therapeutics by 234.2% during the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after buying an additional 3,262 shares during the period. Pinnacle Wealth Management Advisory Group LLC bought a new position in Bicycle Therapeutics in the 4th quarter worth approximately $71,000. Ausdal Financial Partners Inc. acquired a new stake in Bicycle Therapeutics in the 2nd quarter valued at approximately $70,000. Finally, Vontobel Holding Ltd. bought a new stake in Bicycle Therapeutics during the 4th quarter valued at $71,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics News Summary

Here are the key news stories impacting Bicycle Therapeutics this week:

• Positive Sentiment: Q4 results materially beat expectations — Bicycle reported EPS of ($0.29) vs. consensus ($1.00) and revenue of $47.95M vs. $7.08M, a large topline surprise that supports the company’s commercial progress and clinical outlook. Read More.
• Neutral Sentiment: Short‑interest reports show a “large increase” flagged for March but list zero shares and NaN changes; the short‑interest ratio is reported as 0.0 days — this appears to be a reporting/data anomaly and is unlikely to be a meaningful driver while figures remain inconsistent.
• Negative Sentiment: Oppenheimer cut its price target from $44 to $36 but kept an “outperform” rating — a notable reduction in upside that can weigh on sentiment. Read More.
• Negative Sentiment: Royal Bank of Canada lowered its target from $11 to $7 and moved to “sector perform” — another downward revision that reduces analyst‑implied valuation. Read More.
• Negative Sentiment: Citizens Jmp trimmed its target from $12 to $8 while maintaining “market outperform” — a cut that may temper near‑term enthusiasm. Read More.
• Negative Sentiment: Needham lowered its target from $24 to $15 but kept a “buy” rating — another sizable reduction in analyst upside that could pressure the stock despite the buy rating. Read More.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.